Benitec Biopharma (NASDAQ:BNTC) Price Target Raised to $16.00

Benitec Biopharma (NASDAQ:BNTC) had its price target raised by JMP Securities from $10.00 to $16.00 in a report published on Monday morning, Benzinga reports. JMP Securities currently has a market outperform rating on the biotechnology company’s stock.

Benitec Biopharma Stock Down 2.0 %

Shares of BNTC opened at $6.72 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.62 and a quick ratio of 3.62. Benitec Biopharma has a one year low of $1.86 and a one year high of $9.01. The stock’s fifty day moving average is $4.99 and its 200-day moving average is $3.85.

Benitec Biopharma (NASDAQ:BNTC) last announced its earnings results on Tuesday, February 13th. The biotechnology company reported ($2.64) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Benitec Biopharma stock. Adage Capital Partners GP L.L.C. bought a new stake in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 189,188 shares of the biotechnology company’s stock, valued at approximately $572,000. Adage Capital Partners GP L.L.C. owned approximately 7.42% of Benitec Biopharma as of its most recent SEC filing. Institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.